Bibliographic Details
| Title: |
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19 |
| Authors: |
Juan G. Ripoll, Sidna M. Tulledge-Scheitel, Anthony A. Stephenson, Shane Ford, Marsha L. Pike, Ellen K. Gorman, Sara N. Hanson, Justin E. Juskewitch, Alex J. Miller, Solomiia Zaremba, Erik A. Ovrom, Raymund R. Razonable, Ravindra Ganesh, Ryan T. Hurt, Erin N. Fischer, Amber N. Derr, Michele R. Eberle, Jennifer J. Larsen, Christina M. Carney, Elitza S. Theel, Sameer A. Parikh, Neil E. Kay, Michael J. Joyner, Jonathon W. Senefeld |
| Source: |
mBio, Vol 15, Iss 5 (2024) |
| Publisher Information: |
American Society for Microbiology, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Microbiology |
| Subject Terms: |
antibody therapy, SARS-CoV-2, immunocompromised hosts, Microbiology, QR1-502 |
| More Details: |
ABSTRACTAlthough severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients with immunosuppression have poor immunogenic responses to COVID-19 vaccines and remain at high risk of infection with SARS-CoV-2 and hospitalization. In addition, monoclonal antibody therapy is limited by the emergence of novel SARS-CoV-2 variants that have serially escaped neutralization. In this context, there is interest in understanding the clinical benefit associated with COVID-19 convalescent plasma collected from persons who have been both naturally infected with SARS-CoV-2 and vaccinated against SARS-CoV-2 (“vax-plasma”). Thus, we report the clinical outcome of 386 immunocompromised outpatients who were diagnosed with COVID-19 and who received contemporary COVID-19-specific therapeutics (standard-of-care group) and a subgroup who also received concomitant treatment with very high titer COVID-19 convalescent plasma (vax-plasma group) with a specific focus on hospitalization rates. The overall hospitalization rate was 2.2% (5 of 225 patients) in the vax-plasma group and 6.2% (10 of 161 patients) in the standard-of-care group, which corresponded to a relative risk reduction of 65% (P = 0.046). Evidence of efficacy in nonvaccinated patients cannot be inferred from these data because 94% (361 of 386 patients) of patients were vaccinated. In vaccinated patients with immunosuppression and COVID-19, the addition of vax-plasma or very high titer COVID-19 convalescent plasma to COVID-19-specific therapies reduced the risk of disease progression leading to hospitalization.IMPORTANCEAs SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged that evade available anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However, high-titer COVID-19 convalescent plasma continues to be effective against VOCs because of its broad-spectrum immunomodulatory properties. Thus, we report clinical outcomes of 386 immunocompromised outpatients who were treated with COVID-19-specific therapeutics and a subgroup also treated with vaccine-boosted convalescent plasma. We found that the administration of vaccine-boosted convalescent plasma was associated with a significantly decreased incidence of hospitalization among immunocompromised COVID-19 outpatients. Our data add to the contemporary data providing evidence to support the clinical utility of high-titer convalescent plasma as antibody replacement therapy in immunocompromised patients. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2150-7511 |
| Relation: |
https://doaj.org/toc/2150-7511 |
| DOI: |
10.1128/mbio.00400-24 |
| Access URL: |
https://doaj.org/article/ecf5af76d7154c2cbf889ff5abdea430 |
| Accession Number: |
edsdoj.f5af76d7154c2cbf889ff5abdea430 |
| Database: |
Directory of Open Access Journals |
